GlassScriptPhysician profile
Sameer Al-Shweiki
NPI 1508275835
$7,339.02
in general payments reported to CMS, 2019-2025
29 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,188 · 2022: $1,102 · 2023: $1,597 · 2024: $1,204 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,763.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $957.77 | 2021-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $575.10 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $473.42 | 2022-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $451.45 | 2023-2025 | Izervay |
| Rxsight INC | $295.62 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Abbvie INC. | $262.40 | 2022-2025 | Ozurdex |
| Allergan, INC. | $250.37 | 2021 | |
| Mallinckrodt Hospital Products INC. | $211.21 | 2022 | |
| Oyster Point Pharma, INC. | $200.37 | 2023 | Tyrvaya |
| Alcon Vision LLC | $197.94 | 2024 | Clareon, Constellation |
| Sight Sciences, INC. | $159.37 | 2024 | Omni Surgical System |
| Alimera Sciences, INC. | $154.32 | 2021-2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $149.59 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Coherus Oncology, INC. | $149.45 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $135.00 | 2022 | |
| Merz Pharmaceuticals, LLC | $132.35 | 2023 | Xeomin |
| Bausch & Lomb Americas INC. | $129.23 | 2023-2024 | Miebo, Xiidra |
| Dompe US, INC. | $125.00 | 2023 | Oxervate |
| Glaukos Corporation | $115.61 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $115.20 | 2022 | |
| Biogen, INC. | $91.19 | 2022 | |
| Lombart Brothers, INC. | $60.28 | 2023 | Opd-III |
| Novartis Pharmaceuticals Corporation | $49.22 | 2021-2023 | |
| Harrow Eye, LLC | $44.72 | 2024-2025 | Iheezo, Triesence |
| Johnson & Johnson Surgical Vision, INC. | $37.35 | 2022-2023 | One Series Ultra |
| Amgen INC. | $18.06 | 2024 | Pavblu |
| Pacira Pharmaceuticals Incorporated | $17.92 | 2024 | Exparel |
| Eyevance Pharmaceuticals LLC | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Al-Shweiki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.